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Increasing evidence suggests that loss of b cell char-
acteristics may cause insulin secretory deficiency
in diabetes, but the underlying mechanisms remain
unclear. Here, we show that Rfx6, whose mutation
leads to neonatal diabetes in humans, is essential
tomaintain key features of functionally mature b cells
in mice. Rfx6 loss in adult b cells leads to glucose
intolerance, impaired b cell glucose sensing, and
defective insulin secretion. This is associated with
reduced expression of core components of the
insulin secretion pathway, including glucokinase,
the Abcc8/SUR1 subunit of KATP channels and
voltage-gated Ca2+ channels, which are direct tar-
gets of Rfx6. Moreover, Rfx6 contributes to the
silencing of the vast majority of ‘‘disallowed’’ genes,
a group usually specifically repressed in adult b cells,
and thus to the maintenance of b cell maturity. These
findings raise the possibility that changes in Rfx6
expression or activity may contribute to b cell failure
in humans.
INTRODUCTION
The mammalian pancreas comprises an exocrine compartment,
secreting digestive enzymes into the intestine, and an endocrine
compartment, secreting hormones in the bloodstream. Pancre-
atic endocrine cells are grouped in small clusters of cells, the
islets of Langerhans, containing different cell types secreting
distinct hormones. Islet cells include b cells, which secrete insu-
lin, the hormone stimulating glucose uptake in peripheral tissues.
Briefly, glucose enters b cells by facilitated diffusion and, after
phosphorylation by glucokinase (Iynedjian, 1993), is metabolized
by aerobic glycolysis (Sekine et al., 1994), producing metabolic
signals such as a rise in ATP/ADP concentration (Tarasov
et al., 2012). The latter in turn closes ATP-sensitive K+ channels,
causing membrane depolarization and the subsequent opening
of voltage-gated Ca2+ channels (Yang and Berggren, 2006).Cell ReCa2+ influx then stimulates the exocytosis of insulin granules
(Rutter, 2004).
Diabetes is a chronic metabolic disease characterized by
hyperglycemia due to defective insulin secretion, insulin action,
or both. b cells are lacking in type 1 diabetes, while in type 2 dia-
betic patients, b cells cannot compensate for the increased
insulin demand due to their reduced capacity to secrete insulin
in response to high blood glucose. Alterations in both b cell
mass (Butler et al., 2003; Marselli et al., 2013; Rahier et al.,
2008) and function (Rosengren et al., 2012) are likely to
contribute to the overall secretory deficiency observed in type
2 diabetes (Rutter, 2014). Recently, it has been proposed that
b cell dysfunction in type 2 diabetes might also result from a
mechanism of dedifferentiation, which would compromise b
cell function (Talchai et al., 2012) and contribute to the develop-
ment of the disease together with cell death and decreased b
cell mass. This hypothesis, which builds on earlier findings
(Jonas et al., 1999), has been based on the observation that
ablation of FoxO1 transcription factor in adult b cells in mice
caused hyperglycemia with a concomitant reversion of b cells
to a progenitor- or a-like state. Along the same lines, additional
loss-of-function studies in adult b cells revealed that NeuroD1
(Gu et al., 2010), Nkx6.1 (Taylor et al., 2013), or Pdx1 (Gao
et al., 2014) transcription factors are important to maintain the
maturity and differentiated state as well as the insulin-secretive
function of b cells. Thus, it appears that the loss of key b cell
transcription factors results in the loss of both b cell identity
and function.
Rfx6 is a winged-helix transcription factor that has been
shown to be essential for islet cell development in zebrafish
(Soyer et al., 2010), Xenopus (Pearl et al., 2011), mice (Smith
et al., 2010), and humans (Concepcion et al., 2014; Pearl et al.,
2011; Smith et al., 2010; Spiegel et al., 2011). Rfx6 null mice
lack all endocrine cells (excepting PP cells), including b cells,
and die shortly after birth. It was thus concluded that Rfx6 is
necessary for insulin production during embryogenesis (Smith
et al., 2010). In humans, mutations in RFX6 have been reported
to be the cause of the Mitchell-Riley syndrome, an autosomal-
recessive syndrome of neonatal diabetes and small bowel
atresia, often associated with intestinal malabsorption (Concep-
cion et al., 2014; Smith et al., 2010; Spiegel et al., 2011). Clustersports 9, 2219–2232, December 24, 2014 ª2014 The Authors 2219
Figure 1. Deletion of Rfx6 Downstream of Ngn3 Results in the Loss of Insulin-, Glucagon-, Somatostatin-, and Ghrelin-Producing Islet Cells
in Newborn Mice
(A–F) Immunofluorescence experiments on pancreata from controls and Rfx6DEndo pups at postnatal day 0 (P0). Staining for insulin and glucagon (green) and Rfx6
(red) showing efficient deletion of Rfx6 and strong reduction of insulin- and glucagon-expressing cells in Rfx6DEndo mutants (A and B). (B) and (F) show very rare
(legend continued on next page)
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of chromogranin A-positive hormone-negative cells have been
reported in the pancreas of several patients, suggesting a crit-
ical role for RFX6 in the formation of islet and b cells in humans.
The complex spatiotemporal expression pattern of Rfx6 in mice,
namely its broad expression very early in the gut and pancreas
endoderm and then its restriction to developing endocrine
cells in the embryo and its maintenance in adult islets, including
b cells (Smith et al., 2010; Soyer et al., 2010), suggests multiple
functions at different stages and in different organs. Thus, the
phenotype of Rfx6 null mice might result from multiple defi-
ciencies during development. Importantly, the postnatal lethality
of Rfx6/ pups precluded the study of Rfx6 function in adult
b cells. Therefore, to decipher the multiple functions of Rfx6,
we generated a floxed allele. Conditional inactivation of Rfx6
in developing endocrine cells phenocopies the null phenotype,
demonstrating that Rfx6 controls islet development down-
stream of the proendocrine transcription factor Ngn3. Condi-
tional inactivation of Rfx6 in adult b cells led to insulin secretion
deficiency and glucose intolerance, although insulin was still
produced. Removal of Rfx6 perturbs key molecular traits of
functional b cells with the reduction in expression of glucoki-
nase, the ATP-sensitive K+ channel Abcc8/SUR1, as well as
eight voltage-gated Ca2+ channel genes, some of which are
direct targets of Rfx6. Collectively, lowered levels of these
core components of the insulin secretion pathway seem likely
to underlie defective insulin secretion. Unexpectedly, we found
that inactivation of Rfx6 in adult b cells caused the re-expres-
sion of the ‘‘disallowed’’ genes (Pullen et al., 2010; Quintens
et al., 2008; Thorrez et al., 2011), a set of genes expressed nor-
mally in most (if not all) mammalian tissue but selectively and
highly repressed in mouse mature b cells. This finding reveals
a common repression mechanism of disallowed gene expres-
sion in b cells involving a unique transcription factor. Taken
together, our data show that Rfx6 inactivation in b cells causes
decreased expression of b cell-specific genes combined with
the upregulation of disallowed genes, a feature of immature b
cells, demonstrating that Rfx6 can act as an activator or
repressor of transcription. Thus, the present study demon-
strates that Rfx6 is essential for the maintenance of the differen-
tiated state and functional identity of adult b cells. Therefore,
Rfx6 might be an interesting target should ‘‘b cell-identity
drugs’’ be developed in the future as a novel therapeutic strat-
egy in type 2 diabetes.
RESULTS
Rfx6 Is Essential for b Cell Differentiation Downstream
of the Proendocrine Transcription Factor Ngn3
To decipher the different roles of Rfx6, we generated a condi-
tional knockout mouse by flanking exon 3, which encodes a
part of the DNA binding domain, by two loxP sites, generating
a null allele (Figure S1). To determine the role of Rfx6 specif-sections where hormone-positive cells were found. Staining for PP (green) and
hormones (insulin, glucagon, PP, somatostatin) in green and the panendocrine ma
which do not express any of the islet hormones, are found in the pancreas of Rf
(G–W) qRT-PCR experiments for Rfx6, hormones, and transcription factors cont
Scale bars, 50 mM. Data are presented as mean ± SD on n = 4 samples; ***p < 0
Cell Reically in the endocrine lineage and circumvent any effect of a
possible endodermal function, we first generated Rfx6DEndo
mutant animals by crossing Rfx6fl/fl mice with Ngn3-Cre mice
(Yoshida et al., 2004). Rfx6 is efficiently deleted in Rfx6DEndo
pancreas (Figure 1G), and like the full-body knockout,
Rfx6DEndo pups are diabetic and die between 2 and 3 days af-
ter birth (not shown). Ins1, Ins2, Gcg, Sst, and Ghr mRNAs are
strongly decreased, while the amount of Ppy transcripts is
increased (Figures 1I–1N). Accordingly, the differentiation of
hormone-expressing cells was strongly impaired (except for
PP), as insulin- glucagon- or somatostatin-expressing cells
are hardly found (Figures 1A–1D). However, although
the overall amount of ChgA mRNA is decreased (Figure 1H),
an endocrine program has been implemented since chromog-
ranin A-positive but hormone-negative cells are found (Figures
1E and 1F). We further characterized the role of Rfx6 down-
stream of Ngn3 by exploring the expression levels of several
important transcription factors controlling islet cell fate and
maturation. Interestingly, Ngn3 transcripts were elevated
4-fold in the pancreas of Rfx6DEndo mutants at birth, suggesting
that after being induced by Ngn3 in endocrine progenitors,
Rfx6 would in turn repress Ngn3 in developing islet cells or
that the number of Ngn3 cells increases (Figure 1W). Cell quan-
tification did not validate the later hypothesis (not shown). Arx
transcripts are low, while those encoding Pax4 are increased
(Figures 1O and 1P). Thus, as proposed for the full knockout
at embryonic stages (Smith et al., 2010), Rfx6 might control
islet subtype specification by repressing the b fate while pro-
moting a destiny in Rfx6DEndo mice (see Discussion). This
increase in Pax4 was, however, not sufficient to induce b cell
development, because the expression of key regulators of in-
sulin transcription (Pdx1, MafA, NeuroD1) as well as Ins1 was
reduced (Figures 1Q, 1T, and 1V). Together, and as reported
in Rfx6 null embryos (Smith et al., 2010), Rfx6DEndo newborns
almost entirely lack insulin-positive cells. These findings
demonstrate that it is Rfx6 function, downstream of Ngn3,
that is essential for b cell generation and that impaired b cell
development does not result from defective endoderm.
Rfx6 Is Not Absolutely Necessary for Insulin Production
in the Adult Mouse Pancreas
Rfx6 expression is maintained in adult islets, including b cells,
suggesting a role in b cell function (Smith et al., 2010; Soyer
et al., 2010). Because of the postnatal lethality of Rfx6/
and Rfx6DEndo mutants, we generated Rfx6fl/fl; Ins1-CreERT2
mice (called hereafter Rfx6Dbeta) to determine the role of Rfx6
in adult b cells. All subsequent experiments, to address the
role of Rfx6 in adult b cells, were performed with 8- to 10-
week-old mice (age of tamoxifen treatment). Ins1-CreERT2
mice specifically and efficiently delete floxed alleles in b cells
upon tamoxifen treatment (Figure S2). Similarly, in Rfx6Dbeta
mice, Rfx6 is efficiently deleted (95%) as early as 5 days afterRfx6 (red) revealed that PP is not dependent on Rfx6 (C and D). Staining for
rker chromogranin A in red show that chromogranin A-positive endocrine cells,
x6DEndo pups (E and F).
rolling islet cell development in Rfx6DEndo pups and wild-type controls at P0.
.001, **p < 0.01, *p < 0.05.
ports 9, 2219–2232, December 24, 2014 ª2014 The Authors 2221
the first tamoxifen injection as shown by quantitative RT-PCR
(qRT-PCR) on whole islets (Figures 2G and S2) and specifically
in insulin-positive b cells (Figures 2A, 2B, and S2). Although
Ins1 transcripts were reduced by 54%–65% (Table S1; Fig-
ure 2H), but not Ins2 (Table S1), insulin peptide, as well as
c-peptide 1 and 2, are still detected in b cells lacking Rfx6
as late as 3 weeks after tamoxifen injections (Figures 2A–2F).
In agreement with these observations, Rfx6DBeta mice do not
develop overt diabetes. Detection of insulin hormone in
Rfx6DBeta islets was surprising, because a previous study sug-
gested that Rfx6 was necessary for insulin production in the
embryonic pancreas (Smith et al., 2010). Using quantitative
chromatin immunoprecipitation (ChIP) in Min6B1 cells (Lilla
et al., 2003), we could not reveal any binding of Rfx6 to any
of the eight predicted X-boxes in a 10 kb region upstream of
Ins1 gene, while in a control experiment, MafA mapped to
the Ins1 promoter region (not shown). Thus, induced inactiva-
tion of Rfx6 in a mature b cell does not preclude the production
of insulin hormone.
Impaired Insulin Secretion and Glucose Intolerance
in Rfx6DBeta Mice
To determine whether glucose homeostasis was perturbed in
Rfx6DBeta mice, we measured the blood glucose concentration
in fasted and ad libitum-fed mice and conducted intraperitoneal
(i.p.) and oral (O) glucose tolerance tests (GTT) in 3-month-old
males, 1 month after tamoxifen treatment. Basal blood glucose
concentration was similar in Rfx6DBeta and control mice when
either fasted or fed (Figure 3A). After 16 hr fasting, glucose
was administrated by either i.p. injection or intragastric gavage
(2 g/kg body weight). In both conditions, mutant mice displayed
significant glucose intolerance (Figures 3B and 3C). Impaired
glucose homeostasis in Rfx6DBeta mice appears not to be due
to defects in b cell mass, a cell mass, or b cell proliferation
under the same conditions (Figure S3). To determine whether
the reduced glucose clearance resulted from altered insulin
levels, we measured plasma insulin in Rfx6DBeta and control
mice 5 days after tamoxifen treatment (Figure 3D). In fasted
animals, the plasma insulin level in Rfx6DBeta and control mice
was similar (mean controls = 0.35 ng/ml; mean mutants =
0.37 ng/ml; n = 7, p > 0.05). However, significant differences
were observed following i.p. glucose injection (3 g/kg body
weight), as glucose-induced insulin secretionwasmuch less effi-
cient in Rfx6DBeta mice (Figure 3D). Both the first- and second-
phase responses were reduced in mutant mice. To determine
whether the defect was islet autonomous, we purified islets
from Rfx6DBeta and control adult mice under the same conditions
and performed ex vivo glucose-stimulated insulin secretion
(GSIS) and KCl-stimulated insulin secretion (KCl-SIS) studies
(Figure 3E). The amount of secreted insulin was normalized
to the total insulin content, which was identical in controls and
mutants (not shown), confirming that Rfx6 is not key for insulin
production in adult b cells. Clearly, the extent of insulin secretion
in response to a glucose or KCl stimulus was reduced in mutant
islets compared with controls. Notably, the altered KCl-induced
response suggests that the defective insulin secretion might
result from glucose-independent depolarization defects. These
results suggest that impaired glucose clearance results from2222 Cell Reports 9, 2219–2232, December 24, 2014 ª2014 The Autinsulin secretory failure that we detect as early as 1 week after
Rfx6 deletion both in vivo and ex vivo (in islets).
Rfx6 Binds to X-Boxes in the Gck and Abcc8 Genes,
and Their Expression Is Strongly Decreased
in Rfx6DBeta Islets
Next, our goal was to decipher the molecular basis underlying
defective insulin secretion and glucose intolerance in Rfx6DBeta
mice. Therefore, we performed a series of qRT-PCR experi-
ments to measure the expression of key regulators of glucose
simulated insulin secretion in islets isolated from mutant or
control mice, 5 days after tamoxifen treatment. Importantly, we
found that transcripts encoding the key genes Gck and Abcc8
were dramatically reduced (Figures 4A and 4B; Table S1). Gck
encodes glucokinase, an enzyme that controls the first step of
glycolysis and is considered the rate-limiting step in glucose
metabolism (Matschinsky, 2005). Abcc8/SUR1 encodes the reg-
ulatory sulphonylurea-binding subunits of the ATP-sensitive K+
channel (KATP channels) linking glucose metabolism to the elec-
trical activity of b cells (McTaggart et al., 2010). Furthermore,
Ucn3 mRNA, a marker of b cell maturation and also reported
to have a positive effect on GSIS (Li et al., 2007), is strongly
decreased (Figure 4J). In contrast, the expression of the
glucose-facilitated transporter Slc2a2/Glut2, the proconvertase
Pcsk1, and the pore-forming unit of KATP channels (Kcnj11/
Kir6.2) was not altered (Figures 4C–4E). Among the transcription
factors important for b cell function and insulin transcription
tested (MafA, Pdx1, Nkx6.1, Pax6, and NeuroD1), only NeuroD1
and Pax6 transcripts were downregulated (Figures 4F–4I;
Table S1).
To determine whether Rfx6-regulated genes might be direct
targets of Rfx6, we analyzed chromatin immunoprecipitation
sequencing (ChIP-seq) experiments performed in the mouse
b cell line Min6B1 (Lilla et al., 2003) transfected with hemagglu-
tinin (HA)-tagged Rfx6. One peak was detected in the b cell-spe-
cific Gck promoter region (Figure 4K) overlapping with Pal1 and
Pal2 regions previously demonstrated to contain X-boxes bound
by Rfx3 (Ait-Lounis et al., 2010). Similarly, a peak was observed
in a conserved region of intron 10 of the Abcc8 gene (Figure 4L).
Quantitative ChIP experiments in nontransfected Min6B1 cells,
using an Rfx6 antibody, confirmed that endogenous Rfx6 binds
to the Gck and Abcc8 genes, although less strongly to Gck
(Figures 4M and 4N). Taken together, our results suggest that
Rfx6 is a direct positive transcriptional regulator of Gck and
Abcc8 and that the downregulation of these genes could impact
glucose-stimulated insulin secretion.
Glucose Fails to Induce Normal Increases in ATP/ADP
Ratio and Intracellular Free Ca2+ in Rfx6DBeta Mice
Given the abnormalities in glucose-stimulated insulin secretion
and gene expression described above, we next explored the
possibility that signal generation by the sugar may be impaired
in Rfx6 null b cells. Examined using functional multicellular
imaging within intact islets (Hodson et al., 2013, 2014a), both
phases of the intracellular calcium ([Ca2+]i) response to a step
increase in glucose concentration were sharply (50%–60%)
reduced by Rfx6 deletion (Figures 5A and 5D). A smaller
(20%) reduction was also apparent in the overall number ofhors
Figure 2. Insulin Is Produced in Adult b Cells
Lacking Rfx6
(A–F) Immunofluorescence staining on controls and
Rfx6DBeta (Rfx6fl/fl; Ins1-CreERT2) adult mice,
3 weeks after the first day of tamoxifen injections
(8- to 10-week-old mice were injected once a day
during 3 consecutive days). Staining for insulin
(green, A and B) and Rfx6 (red, A and B) reveal
insulin expression despite efficient deletion of
Rfx6 in b cells of Rfx6DBeta mice (white arrows in
B). Staining for c-peptide1 (red, C and D) and c-
peptide2 (red, E and F) supports efficient insulin
synthesis.
(G–L) qRT-PCR experiments on islets purified from
controls and Rfx6DBeta adult (8- to 10-week-old)
mice 5 days after tamoxifen injections revealing
rapid and specific deletion of Rfx6 (G) in b cells
and decreased Ins1 transcription (H), while the
expression of Gcg, Ppy Sst and ChgA is unaltered.
Grey triangles indicate the days of tamoxifen in-
jections. Yellow and red arrows point to examples
of b cells expressing Rfx6 in controls and insulin-
negative/Rfx6-positive cells in Rfx6DBeta mice,
respectively.
Scalebars, 50mM.Dataarepresentedasmean±SD
on n = 4 samples; ***p < 0.001, **p < 0.01, *p < 0.05.
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Figure 3. The Deletion of Rfx6 in b Cells
Causes Glucose Intolerance due to Defec-
tive Insulin Secretion
(A–C) Exploration of glucose metabolism in adult
(12- to 14-week-old) controls (n = 8) and Rfx6DBeta
(n = 7) males under normal diet 4 weeks after
tamoxifen injections. Blood glucose levels are
measured in overnight (16 hr)-fasted and ad libi-
tum-fed animals 1month after tamoxifen injections
(A). Intraperitoneal glucose tolerance test (IPGTT)
after 16 hr fasting in male mice 1 month after
tamoxifen injections (B). Oral glucose tolerance
test (OGTT) after 16 hr fasting in male mice
1 month after tamoxifen injections (C).
(D) Histogram representing the plasma insulin
levels of control and Rfx6DBeta mice (9–11 weeks
old) during an in vivo glucose-stimulated insulin
secretion test (n = 6) performed 5 days after
tamoxifen injections.
(E) Histogram representing the insulin released
during an ex vivo glucose- and KCl-stimulated
insulin secretion tests on islets purified from con-
trols and Rfx6DBeta (n = 4) mice (9–11 weeks old),
5 days after tamoxifen injections.
Data are presented as mean ± SD; *p < 0.05, **p <
0.01, ***p < 0.001.responsive cells (Figure 5B). These changes were accompanied
by more modest, but significant, defects in the response to de-
polarization with KCl (Figures 5C and 5E), suggesting a defect
downstream of metabolic signal generation by glucose. Defects
in the latter process were, nonetheless, highlighted by a sub-
stantial (60%) impairment in glucose-induced cytosolic ATP/
ADP increases (Hodson et al., 2014b; Tarasov et al., 2012) (Fig-
ures 5F and 5G), consistent with lowered Gck expression.
In line with the above defects in calcium influx, RNA
sequencing (RNA-seq) performed on Rfx6DBeta and control
whole islets, 5 days after tamoxifen treatment, revealed that
the expression of eight voltage-dependent calcium channels
(VDCCs) transcripts was downregulated by the deletion of Rfx6
in adult b cells (Table S2). These genes included Cacna1a,
Cacnb2, Cacna1d, and Cacna1c, which are among the most
abundantly expressed VDCCs in rodent islets (Table S2). Down-
regulation of Cacna1d, Cacna1c, and Cacnb2 was confirmed by
RT-PCR (Figures 5H–5J). ChIP sequencing (ChIP-seq) inMin6B1
cells revealed that Rfx6 binds to two of the Rfx6-dependent2224 Cell Reports 9, 2219–2232, December 24, 2014 ª2014 The AuthorsVDCC genes, at X-boxes in intron 1 of
Cacna1c andCacnb2 genes, respectively
(Figures 5K and 5L), suggesting that Rfx6
can directly regulate these genes, a result
confirmed by quantitative ChIP (Figures
6M–6O). Collectively, these data suggest
that compromised insulin secretion in
Rfx6-deficient b cells is the consequence,
at least in large part, of the combined
alteration of key steps in glucose
signaling due to a failure of Rfx6 to
directly promote the expression of key
genes. These include both glycolysis,impaired by downregulation of Gck, and Ca2+ influx, affected
by the repression of voltage-gated calcium channels.
Derepression of theDisallowedGenes in bCells Lacking
Rfx6
We next sought to determine whether additional mechanisms
may also play a role in defective glucose-induced insulin secre-
tion in Rfx6 null b cells. Rfx transcription factors have been re-
ported to be either activators or repressors of transcription (Aftab
et al., 2008). Accordingly, RNA-seq revealed a series of genes
with a higher expression in b cells after Rfx6 deletion. Surpris-
ingly, we found a specific upregulation of the so-called disal-
lowed or forbidden genes. Disallowed genes are genes that
are abundantly expressed in most tissues but selectively
repressed in adult mouse b cells. Two different studies identified
a total of 68 of these genes by microarray analysis (Pullen et al.,
2010; Thorrez et al., 2011). We found that 54 out of the 68 disal-
lowed genes reported were upregulated in Rfx6DBeta islets,
including the 11 common genes identified in both studies (Pullen
andRutter, 2013), namelySlc16a1, Ldha,Pdgfra, Igfbp4,Cxcl12,
Oat, Smad3, Lmo4, C1qbp, Maf, and Cd302 (Table S3). We
confirmed the upregulation of some of the selected genes by
qRT-PCR: Ldha, Slc16a1, Pdgfra, and Igfbp4 (Figures 6A–6D).
ChIP-seq and quantitative ChIP in Min6B1 cells revealed that
Rfx6 binds to a conserved region approximately 10 kb upstream
of Ldha gene (Figures 6E and 6F), suggesting that Rfx6 could
directly regulate the repression of this gene in b cells. Some of
the disallowed genes have been reported to modulate insulin
secretion (see Discussion and Pullen and Rutter, 2013). Thus,
by repressing the disallowed genes, Rfx6 contributes to the
maintenance of b cell identity and function.
DISCUSSION
Previous studies have revealed that Rfx6 is required during
development in rodents and in humans for the generation of b
cells (Smith et al., 2010). The present work now demonstrates
that this factor is also essential for the maintenance of the func-
tional identity of the adult b cell.
Rfx6 and Insulin Production
To determine the role of Rfx6 in b cell function, we conditionally
and specifically inactivated this factor in mature adult b cells. The
resulting Rfx6DBeta mice are glucose intolerant in contrast to
the phenotype of the Rfx6 null mice, which die shortly after birth
with severe and sustained hyperglycemia (>600 mg/dl). This
difference indicates that Rfx6 has a distinct function in adult b
cells that is different from its earlier function in the embryonic
pancreas. In the embryo, our data in Rfx6DEndo mouse pancreas
clearly show that Rfx6 is required downstream of Ngn3 for
proper b cell development, when cells are already committed
to an islet fate. It is unclear whether the strongly impaired expres-
sion of insulin transcripts and peptide in the Rfx6DEndo embryonic
pancreas reflects a blockade in the b cell differentiation program
or a direct regulation of the transcription of Insulin genes by Rfx6.
However, it is likely that Rfx6 has a very early function down-
stream of Ngn3 and implements genetic programs essential for
islet subtype specification to proceed. This hypothesis is sup-
ported by the up- and downregulation of Pax4 and Arx, respec-
tively (also observed in the constitutive Rfx6 knockout; our own
data and Smith et al., 2010), known to control b-d versus a des-
tiny (Collombat et al., 2003). One possibility would be that in a
wild-type situation, Rfx6 would favor the a destiny by promoting
Arx expression and simultaneously blocking the b fate by repres-
sing Pax4. However, Rfx6 must have an additional role; other-
wise, we would have observed an increased number of b cells
in Rfx6DEndo embryos, which is not the case. The maintenance
of genericmarkers of endocrine differentiation such as chromog-
ranin A testifies that endocrine differentiation proceeds in the
absence of Rfx6. On the other hand, the strong downregulation
of Ins1, Ins2, Gcg, Ghr, and Sst mRNAs suggests that Rfx6
implements a genetic program required for hormone production
in embryonic islet cells. In adult mice, the overall production
of insulin is not altered in Rfx6DBeta islets and thus Rfx6 is not
indispensible for insulin production in b cells. However, Ins1 tran-
scripts are decreased when Rfx6 is deleted in b cells, while Ins2
transcripts do not vary. A similar result has been reported in miceCell Relacking NeuroD1 in b cells (Gu et al., 2010), although Ins1 was
reduced by 95% in this model, in contrast to 65% in Rfx6DBeta
islets. ChIP-seq and quantitative ChIP in Min6B1 cells did not
reveal any binding of Rfx6 to putative X-boxes, suggesting that
Rfx6 does not directly regulate Ins1 gene, although we cannot
exclude that it is the case in bona fide b cells. Furthermore, like
in mice lacking NeuroD1 in b cells, the expression of other regu-
lators of Insulin transcription such as MafA, Nkx6.1, and Pdx1 is
unchanged in Rfx6DBeta islets, suggesting that the reduction
in Ins1 transcripts results from decreased levels of NeuroD1.
Decreased Ins1 transcript levels could also result from low
Pax6, which is necessary for insulin synthesis in adult b cells
(Hart et al., 2013). Importantly, we observed a downregulation,
and not a complete loss, of NeuroD1 and Pax6 and suspect
that levels of these transcription factors are sufficient to account
for the insulin mRNA levels measured in Rfx6DBeta islets. How-
ever, we did not observe any signal reduction in anti-insulin
immunofluorescence experiments, and total insulin content
was not affected either, probably because the reduction of
Ins1mRNA was less severe compared to mice lacking NeuroD1
in b cells. Such a decrease in Ins1 transcripts without any signif-
icant effect on insulin content has been described previously,
such as in MafA-deficient mice (Zhang et al., 2005), and may
reflect alterations in mRNA translation.
Rfx6 and Insulin Secretion
We found that without the transcription factor Rfx6, insulin secre-
tion is impaired in b cells and mice become glucose intolerant.
Defective insulin secretion resulted from a combined effect to
reduce expression of three core components of the glucose-
stimulated signaling pathway in b cells, which we show to be
direct targets of Rfx6. First, mRNAs encoding the glucose sensor
Glucokinase were decreased (75%) in Rfx6DBeta islets. Gluco-
kinase is the flux-generating enzyme of oxidative glycolysis,
coupling blood glucose concentration to metabolic signals in b
cells, ultimately leading to rises in cytosolic ATP/ADP ratios trig-
gering the closure of KATP channels and subsequent membrane
depolarization. Gene-deletion experiments in mice have demon-
strated that Gck is essential for insulin secretion and mainte-
nance of glucose homeostasis and that reduction in Gck gene
dosage (Gck+/ mice) is sufficient to induce mild hyperglycemia
(Terauchi et al., 1995).We thus believe that decreasedGck levels
are the principal cause of the failure of the cytosolic ATP/ADP
ratio to increase appropriately upon glucose stimuli in Rfx6DBeta
islets. Interestingly, insulin secretion reaches a plateau at 11 mM
glucose in Rfx6DBeta islets, and further increases in glucose con-
centrations have no effect on insulin secretion, demonstrating
that the response to glucose is saturated. Though other steps
in the pathway may also be affected, this change in glucose
dose response is consistent with a shift in the control of glyco-
lytic flux toward other hexokinase family members (HKI-III) with
lower Michaelis constants for the sugar. Second, we found
that Abcc8/SUR1 transcripts encoding the regulatory subunit
of the ATP-sensitive K+ channel (KATP channels) are downregu-
lated as well in Rfx6DBeta islets. Thus, we propose that lowered
Abcc8, which would tend to raise the resting plasma membrane
potential at low glucose while impairing stimulation by the sugar
(Nenquin et al., 2004), combined with suboptimal increases inports 9, 2219–2232, December 24, 2014 ª2014 The Authors 2225
Figure 4. Rfx6 Regulates a Subset of Genes Controlling b Cell Function and Directly Targets Gck and Abcc8
(A–J) qRT-PCR experiments forGck,Kcnj11,Abcc8, Slc2a2, Pcsk1,Pax6,MafA,Nkx6.1,Pdx1, andUcn3 on islets purified from controls and Rfx6DBeta adult mice
(9–11 weeks old), 5 days after tamoxifen injections. Grey triangles indicate the days of tamoxifen injections.
(legend continued on next page)
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ATP/ADP ratios, alters b cell membrane excitability. This, in turn,
will affect the opening of voltage-dependent Ca2+ channels, at
least partially explaining impaired glucose-induced Ca2+ influx.
Third, we found that Rfx6 is also critical for the expression of
several voltage-dependent calcium channels mRNAs of the L,
R, and P/Q type, which are downregulated in Rfx6DBeta islets.
These include central players such as the L-type Ca2+ channel
subunit alpha 1C (Cacna1c, also named as Cav1.2) and the
R-type Ca2+ channel alpha 1E (Cacna1e, also named Cav2.3)
subunits, which have been shown to be essential for insulin
secretion in mice by regulating first and second phases of secre-
tion, respectively (Jing et al., 2005; Schulla et al., 2003). Thus, in
addition to decreased glycolysis and reduced levels of KATP
channel Abcc8/SUR1 subunits, lowered voltage-gated Ca2+
channels likely contributes to the impaired elevation of intracel-
lular Ca2+ and accounts for defective KCl-stimulated insulin
secretion. Finally, we noted that the zinc transporter Slc30a8
(ZnT8), required for normal insulin crystallization and secretion
(Rutter, 2010), was also repressed after Rfx6 deletion (Table
S1), suggesting that later events in the exocytotic process may
also be affected. Nevertheless, and despite multiple deficiencies
in several steps controlling glucose-induced secretion, Rfx6DBeta
are only mildly glucose intolerant. As we did not reveal any
increase in b cell mass, we suggest that Rfx6DBeta mice compen-
sate their impaired insulin secretion by other mechanisms, which
may include an increased insulin sensitivity or higher secretion
of glucoincretins.
Importantly, ChIP experiments in the mouse b cell line Min6B1
suggest that Rfx6 binds to X-boxes in Gck, Abcc8, and the
VDCC Cacna1c and Cacnb2 genes. These results, together
with the expression data of Rfx6DBeta islets (RNA-seq), clearly
suggest that Rfx6 controls b cell function in the adult by directly
regulating the expression of key core components of the insulin-
secretion pathway. Interestingly, Gck has been previously re-
ported to be a direct target of Rfx3 (Ait-Lounis et al., 2010).
The fact that we independently found, by an unbiased method
(ChIP-seq), that Rfx6 binds to the very same region in the Gck
promoter as Rfx3 strongly supports that Rfx transcription factors
are important regulators of Gck expression. However, Rfx3 (Rfx3
expression is unaffected in Rfx6DBeta islets) was not sufficient to
compensate for the absence of Rfx6, regarding Gck expression,
suggesting that Rfx3-Rfx6 heterodimers bind to the Gck pro-
moter for the optimal transcription of Gck gene. Binding of
Rfx3 to Abcc8 or voltage-dependent Ca2+ channel genes has
not been reported, and although Rfx6 and Rfx3 might coregulate
other targets genes, the extent of the functional redundancy of
both transcription factors in b cell function and insulin secretion
cannot be evaluated, as the phenotype of mice with a deletion
ofRfx3 in adult b cells has not been described. Likewise, whether
a small but significant (30%) decrease in Rfx5 expression
(Table S1) observed here also contributes to the phenotype of
Rfx6 null adult mice remains a question for the future.(K and L) ChIP-seq (anti-HA) data showing Rfx6 binding peaks in Abcc8 and Gc
(M and N) Quantitative ChIP (anti-Rfx6 antibody) in Min6B1 cells illustrating th
preimmune and anti-Rfx6 serum.
Data are presented as mean ± SD on n = 4–5 samples; **p < 0.01, *p < 0.05.
Cell ReRfx6 Contributes to the Silencing of the Disallowed
Genes and Maintenance of b Cell Maturity
A group of disallowed or ‘‘forbidden’’ housekeeping genes has
recently been described to be selectively repressed in b cells.
The potential role of their repression in b cell function and
glucose homeostasis (discussed in detail in Pullen and Rutter,
2013) is still to be fully elucidated. However, it has been pro-
posed for the two founder members, lactate dehydrogenase A
(Ldha) and monocarboxylate transporter-1 (MCT-1/Slc16a1),
that their downregulation in b cells prevents lactate and pyru-
vate, produced from muscle during exercise, from inappropri-
ately stimulating insulin release (Thorrez et al., 2011). At present,
it is unclear whether a general mechanism controls the silencing
of all (or most) of the disallowed genes. However, epigenetic
mechanisms such as the trimethylation of histone H3 on lysine
27 (H3K27me3) has been suggested to be the cause of disal-
lowed gene repression, as H3K27me3 was found present on
Slc16a1 promoter (van Arensbergen et al., 2010) and a few other
forbidden genes (Cxcl12, Acot7, Nfib, Mgst1, and Maf) (Pullen
and Rutter, 2013). Likewise, DNA methylation is reported also
to be involved in the repression of some (e.g., Acot7) (Dayeh
et al., 2014), but not other (Slc16a1/MCT1) (Pullen et al., 2011),
members of this family. On the other hand, microRNAs have
also been reported to downregulate Slc16a1 (Pullen et al.,
2011). Our current study provides evidence of another mecha-
nism whereby a transcription factor (Rfx6) may act as a master
regulator, repressing disallowed genes and serving as a com-
mon mechanism for disallowed gene downregulation, as we
found that 79% of these genes were significantly upregulated
in Rfx6DBeta islets. We found that Rfx6 binds to an X-box located
10 kb upstream of Ldha start site in Min6B1 cells, supporting
direct repression. Along the same lines, and further supporting
the notion that Rfx6 directly targets disallowed genes, we iden-
tified Rfx6 binding peaks in the vicinity of 32 out of 54 (59%)
Rfx6-repressed disallowed genes (Table S3). Of note, increased
expression of Ldha has also been described when NeuroD1 is
deleted in b cells (Gu et al., 2010). We thus cannot exclude
that the repression of NeuroD1, observed in Rfx6DBeta islets,
also contributes to elevated Ldha transcript levels, a feature of
neonatal b cells, in contrast to mature b cells, which have low
amounts of Ldha (Gu et al., 2010; Sekine et al., 1994). Impor-
tantly, other members of the disallowed family have not been
reported to be dysregulated in NeuroD1-deficient b cells. Taken
together, our own and others’ data suggest that repression of
disallowed genes is achieved by multiple mechanisms including
transcription factor-mediated repression of gene expression.
Tissue-specific gene repression is thought to proceed during
the maturation of islet cells during postnatal stages (Thorrez
et al., 2011), a period when b cells acquire a mature GSIS
(Blum et al., 2012). Interestingly, we did not observe any change
in the expression of disallowed genes in the embryonic pancreas
of Rfx6-deficient mice (data not shown). Thus, we propose thatk genes in 3HA-Rfx6 transfected Min6B1 cells.
e binding of Rfx6 to X-boxes indicated in (K) and (L). PI and Rfx6 stand for
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Figure 5. Impaired ATP/ADP Ratio and Calcium Trafficking in Glucose Stimulated b Cells in Rfx6DBeta Islets
(A) Mean (±SEM) Ca2+ traces following elevation of glucose from 3 mM to 11 mM (n = 16 islets from five mutants and six controls). Insets are the amplitude and
area under the curves.
(legend continued on next page)
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Figure 6. Rfx6 Targets and Represses Disallowed Genes in b Cells
(A–D) qRT-PCR showing the downregulation of Ldha, Slc16a1, Igfbp4, and Pdgfra in islet cells from Rfx6DBeta mice (9–11 weeks old), 5 days after tamoxifen
injections compared to controls (n = 4).
(E and F) ChIP-PCR and ChIP-seq revealing the binding of Rfx6 on one X-box in Ldha gene in Min6B1 cells (n = 3).
Data are presented as mean ± SD; **p < 0.01, *p < 0.05.Rfx6 is essential to establish and maintain the repression of the
disallowed genes and thereby the maturity of b cells. The extent
to which perturbation of disallowed gene expression contributes
to the phenotype of Rfx6DBeta mice remains to be studied.
However, it was shown previously that overexpression of Ldha
diminishes glucose-stimulated insulin secretion in islets (Ain-
scow et al., 2000; Ishihara et al., 1999). Moreover, forced over-
expression of Slc16a1 in b cells leads to insulin secretion in
response to muscle-derived pyruvate (Pullen et al., 2012) and
is thought to be responsible for exercise-induced hyperinsulin-(B) Proportion of fluo2-loaded cells that respond to 11 mM glucose.
(C) Mean (±SEM) Ca2+ traces following application of the depolarizing stimulus 3
(D) Representative Ca2+ responses to 11mM glucose in a single islet (average of
(E) Representative Ca2+ responses to 30 mM KCl in a single islet.
(F) Mean (±SEM) Perceval traces recording ATP dynamics following elevation of g
and four controls). Insets are the amplitude and area under the curves of cytoso
(G) Proportion of Perceval-expressing cells, shown to represent beta cells (Hods
(H–J) qRT-PCR revealing the decrease in the transcription of VDCCs in Rfx6DBet
(K–O) ChIP-seq (K and L) and quantitative ChIP (M–O) showing the binding of Rfx6
in (M) and (N) stand for preimmune and anti-Rfx6 serum.
Data are presented as mean ± SD; ***p < 0.001, **p < 0.01.
Cell Reism in humans (Otonkoski et al., 2007). In addition to Ldha
and Slc16a1, several other disallowed genes potentially impact
insulin secretion and glucose homeostasis, acting as second
messengers controlling insulin secretion or regulating trafficking
of insulin granules (see Pullen and Rutter, 2013 for a review).
Thus, Rfx6 controls b cell maturity and glucose homeostasis
by repression of the disallowed genes and activation of core
component of the insulin secretion pathway, including glucoki-
nase, the Abcc8/SUR1 subunit of KATP channels and voltage-
gated Ca2+ channels.0 mM KCl (n = 18 islets from same animals as A).
about 50 responsive cells per islet).
lucose from 3 mM to 16.7 mM (250 cells from n = 12 islets from four mutants
lic ATP/ADP rises ([ATP/ADP]cyto).
on et al., 2014a) that respond to 16.7 mM glucose.
a islets (n = 4).
on X-boxes of Cacna1c and Cacnb2 genes in Min6B1 cells (n = 3). PI and Rfx6
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We show here that Rfx6 is required for normal b cell identity,
sustaining the expression of signature b cell genes (Gck,
Abcc8) and repressing that of disallowed genes. These findings
raise the possibility that changes in RFX6 expression may
contribute to b cell failure in type 2 diabetes (T2D) in humans.
To date, however, no such changes inRFX6mRNAhave been re-
ported in T2D versus healthy donor b cells (Marselli et al., 2010;
Taneera et al., 2012), despite the increased expression of 15 dis-
allowed genes in human T2D (Pullen and Rutter, 2013). However,
we would point out that these studies involved a relatively small
number of subjects, and therefore, we need to wait for the results
ofmuch larger ongoing trials to concludewhether subtle changes
in RFX6 levels are associated with T2D. Furthermore, changes in
RFX6 activity resulting from altered subcellular localization or
posttranslational modifications cannot be excluded in diseased
islets. Interestingly, fasting hyperglycemia has been reported in
a patient bearing a heterozygote mutation in the RFX6 gene
and SNP susceptibility to T2D, supporting a role for RFX6 in b
cell function in humans (Artuso et al., 2014).
Finally these results suggest that, in addition to having fewer b
cells, sufferers of neonatal diabetes who carry RFX6 mutations
are also likely to have defects in those cells that remain (Mitchell
et al., 2004).Whether these individuals may therefore be suscep-
tible to pharmacological treatments, including sulphonylureas
or GLP-1 analogs, which could prompt insulin release from the
remaining b cells, may be worthy of investigation.
EXPERIMENTAL PROCEDURES
Immunostaining and Morphometric Analysis of Islets
Pancreata were fixedwith 4%paraformaldehyde, cryo- or paraffin embedded,
and stained with the primary and secondary antibodies listed in Supplemental
Experimental Procedures. Antigen retrieval was used prior to staining for
Rfx6. For bromodeoxyuridine (BrdU) detection assays, BrdU (50 mg/kg body
weight) was injected 24 hr before sacrifice to assess proliferation in adult
b cells. For a and b cell mass, quantification was performed every 2 mm and
calculated as described in Figure S3. Four animals of each genotype were
analyzed. Animal experiments were supervised by G.G. (agreement NC67-
59 approved by the Direction des Services Ve´te´rinaires, Strasbourg, France)
in compliance with the European legislation on the care and use of laboratory
animals.
Insulin Secretion Assay
For each animal (n = 4 per genotype, 8–10 weeks old), quadruplicates of five
starved islets were placed in Eppendorf tubes containing 2 ml of Kreb’s buffer
containing 2.8 mM glucose, 11 mM glucose, 16.8 mM glucose, or 2.8 mM
glucose + 30 mM KCl and incubated for 1 hr, and the supernatant was
collected to measure insulin secretion. Quadruplicates of five unstimulated
islets were sonicated and extracted by acid-ethanol. Insulin in supernatants
and islet lysates was measured by ELISA (ultrasensitive insulin ELISA,
ALPCO). Secreted insulin was then normalized with total lysate insulin content
and expressed as a percentage of total insulin.
To measure insulin secretion in vivo, 9- to 11-week-old males were fasted
for 16 hr, and we collected blood from animals (n = 6 per genotype) before
glucose injection and 5, 15, and 30 min after glucose injection. D-glucose
solution (15%) was injected intraperitoneally at 3 g/kg body weight. Plasma
was separated from blood by centrifugation, and circulating insulin was
measured by ELISA (ultrasensitive insulin ELISA, ALPCO).
RNA Sequencing
Total RNA was extracted from adult islets from three controls and three
mutants, and RNA integrity was assessed. After sequencing (Hiseq 2500, 502230 Cell Reports 9, 2219–2232, December 24, 2014 ª2014 The Autbase reads), reads were mapped onto the mm9 assembly of the mouse
genome by using Tophat v1.4.1 (Trapnell et al., 2009) and the bowtie
v0.12.7 aligner (Langmead et al., 2009). Only uniquely aligned reads have
been retained for further analyses.
Calcium and ATP Imaging
Functional multicellular Ca2+-and ATP/ADP-imaging were performed as previ-
ously described (Hodson et al., 2013; Hodson et al., 2014a, 2014b; Tarasov
et al., 2012). Briefly, fluo2-loaded or Perceval-expressing islets were mounted
in a custom-manufactured aluminum heated chamber and perifused with a
HEPES-bicarbonate buffer (120 mM NaCl, 4.8 mM KCl, 24 mM NaHCO3,
0.5 mM Na2HPO4, 5 mM HEPES, 3 mM D-glucose, 2.5 mM CaCl2, and
1.2mMMgCl2) saturated with 95%O2/5%CO2 and adjusted to pH 7.4. During
recording, islets were maintained at 36C and drugs/glucose delivered
through the perfusion system at the indicated concentrations. Excitation
was performed using a 491 nm solid-state laser (Cobalt) coupled to a Yoko-
gawa CSU10 Nipkow spinning disk head, and emitted signals were captured
at 525 ± 50 nm using a Hamamatsu 16-bit electron-multiplying charge-
coupled device. An adenoviral vector was used to deliver cDNA encoding
Perceval into the first few islet layers (multiplicity of infection, 10–100; 48 hr
incubation).
Statistics
Values are presented as mean ± SD, and p values were determined using the
two-tailed Student’s t test with unequal variance. p < 0.05 was accepted as
statistically significant.ACCESSION NUMBERS
RNA-seq and ChIP-seq data have been deposited to the Gene Expression
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